Organisation: forskargrupp


Ämnesklassifikation (UKÄ)

  • Endokrinologi och diabetes


This project aims to develop incretin therapy as a glucose-reducing strategy in type 2 diabetes (T2D). Its particular focus is to understand the mechanisms of incretin therapy and to optimize its clinical positioning. This mission is achieved by an interdisciplinary approach with complementary studies in subjects with T2D, healthy volunteers and experimental animals.

Senaste forskningsoutput

Bo Ahrén, Yuichiro Yamada & Yutaka Seino, 2021 jan, I: Peptides. 135, 170434.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Micaela Morettini, Laura Burattini, Christian Göbl, Giovanni Pacini, Bo Ahrén & Andrea Tura, 2021, I: Frontiers in Endocrinology. 12, 611147.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Bo Ahrén & Giovanni Pacini, 2020 okt 23, I: Journal of Diabetes Investigation.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Visa alla (49)